Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective...

Related Keywords

Russia ,Australia ,Germany ,Ukraine ,German ,Paula Schwartz ,Daniel Vitt ,Jessica Breu ,Edna Kaplan ,Vincent Ossipow ,Richard Rudick ,Development Rd Expenses ,Rx Communications Group ,Nasdaq ,Exchange Commission ,Prnewswire Immunic Inc ,Immunic Inc ,Preclinical Data Published ,Potent Nurr ,Reinforcing Neuroprotective Potential ,Multiple Sclerosis ,Positive Results From Phase ,Clinical Trial ,Celiac Disease Provide Proof Of Concept ,New Therapeutic Approach ,Treat Gastrointestinal Diseases ,Promoting Regeneration ,Bowel Architecture ,Interim Results From Phase ,Vidofludimus Calcium ,Progressive Multiple Sclerosis Expected ,Cash Equivalents ,Investments Expected ,Fund Immunic Into ,Fourth Quarter ,Held Today ,Chief Executive Officer ,Medicinal Chemistry ,Digestive Disease Week ,Strengthened Board ,German Federal Ministry ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Consolidated Statements ,Immunic ,Nc ,